Wockhardt Q1 FY27: Revenue up 36 percent, PAT up 55 percent YoY standalone

Revenue Growth 20pctPat Growth 25pctExceptional ItemResults View source PDF Explain this filing

WOCKPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.0%Reaction day

₹2023.00

prior close

₹1906.60

announcement price

In-mkt

timing

Nifty Smallcap 250market-0.1%-2.9% vs market

Pharmaceuticals peers, median of 165sector-0.1%-2.9% vs sector

On the reaction day the stock moved 2.9 pts less than Nifty Smallcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.0

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.0-0.1-2.9-0.1-2.9

Next day

-6.0+0.1-6.1+0.0-6.0

-8.9-0.1-8.8-0.0-8.9

-5.6+0.1-5.6+0.3-5.9

-4.5-0.4-4.0-0.5-3.9

-6.5-0.2-6.3-1.1-5.4

-9.7-0.7-9.0-1.8-7.9

15d

-6.8+0.1-6.9+0.2-7.0

+9.7+0.4+9.3+1.4+8.4

-2.9-3.2+0.3-1.8-1.1

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Wockhardt Q1 FY27: Standalone revenue up 36 percent YoY at Rs 561 cr; PAT up 55 percent at Rs 107 cr. Consolidated revenue rose 26 percent to Rs 929 cr; PAT swung to Rs 107 cr profit from Rs 108 cr loss YoY, aided by nil exceptional items versus Rs 97 cr charge. EPS Rs 6.62 standalone, Rs 6.55 consolidated. Auditor MSKC and Associates issued an unqualified limited review.

Likely market impact

Strong YoY growth in revenue and profit on standalone and consolidated basis with clean audit; likely positive for stock sentiment.